Xeris Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) announces the release of its fourth quarter and full year 2021 financial results on March 10, 2022, prior to U.S. market open. A conference call and webcast will follow at 8:30 a.m. ET to discuss the results. The company specializes in developing therapies for endocrinology, neurology, and gastroenterology, with products like Gvoke® and Keveyis®. Xeris also has ongoing development programs supported by proprietary formulation technologies.
- Strong product portfolio, including Gvoke® and Keveyis®, addressing significant medical needs.
- Development programs utilizing proprietary technology platforms, enhancing future growth potential.
- None.
To pre-register for the conference call please use this link: https://www.incommglobalevents.com/registration/q4inc/9809/xeris-biopharma-fourth-quarter-2021-financial-results-conference-call-and-webcast/. After registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until
About
Xeris (Nasdaq: XERS) is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. Xeris has three commercially available products; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis®, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect™, supporting long-term product development and commercial success.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220304005074/en/
Investor Contact
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com
312-736-1237
Source:
FAQ
When will Xeris Biopharma release its Q4 2021 financial results?
What time is the Xeris Biopharma conference call for Q4 2021 results?
What products does Xeris Biopharma offer?